Multipel Myeloom

2020 - Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy

2019 - Anticancer Activity and Underlying Mechanism of Phytochemicals against Multiple Myeloma 

2018 - Curcumin‑induced promoter hypermethylation of the mammalian target of rapamycin gene in multiple myeloma cells 

2017 - Effect of the Ginger Derivative, 6-Shogaol, on Ferritin Levels in Patients With Low to Intermediate-1-Risk Myelodysplastic Syndrome-A Small, Investigative Study

2017 - Evidence-Based Review of BioBran/MGN-3 Arabinoxylan Compound as a Complementary Therapy for Conventional Cancer Treatment

2017 - Long-term stabilisation of myeloma with curcumin 

2017 - Long-term follow-up of curcumin treated MGUS/SMM patients – an updated single centre experience

 

 

2016 - Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study 

2015 - B-Cell Disorders and Curcumin

2015 - Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups 

2015 - Stabilisation of Laryngeal AL Amyloidosis with Long Term Curcumin Therapy

2015 - The effect of curcumin (as Meriva) on absolute lymphocyte count (ALC), NK cells and T cell populations in patients with stage 0/1 chronic lymphocytic leukemia

2013 - Curcumin enhances the cytotoxic and chemo-sensitising effects of lenalidomide in human multiple myeloma cells

2013 - Long term use of curcumin in two smoldering multiple myeloma (SMM) patients

2012 - Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebocontrolled cross-over 4g study and an open-label 8g extension study

2012 - Response to Vermorken et al--curcumin and free light chains

2011 - The impact of osteoporosis (as measured by lumbar spine quantitative computed tomography) on disease activity and survival in myeloma patients: a 13-year prospective study

2010 - Vitamin D status may effect the skeletal complications of multiple myeloma

2008 - The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/ paraproteinemia 

2009 - The potential role of curcumin in patients with monoclonal gammopathy of undefined significance – its effect on paraproteinemia and the urinary N-telopeptide of type 1 collagen bone turnover marker

2004 - Nuclear factor–B and STAT3 are constitutively active in CD138 cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis 

2004 - Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance

 

2003 - Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells

2003 - Curcumin (Diferuloylmethane) down-regulates the constitutive activation of nuclear factor–B and IB kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis